Sistema de Salut de Catalunya
[Louro J] Hospital Del Mar Medical Research Institute (IMM), Barcelona, Spain. Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain. Servei d’Epidemiologia i Avaluació, Hospital del Mar, Barcelona, Spain. European Higher Education Area (EHEA) Doctoral Programme in Methodology of Biomedical Research and Public Health in Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Román M, Posso M] Hospital del Mar Medical Research Institute (IMM), Barcelona, Spain. Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain. Servei d’Epidemiologia i Avaluació, Hospital del Mar, Barcelona, Spain. [Comerma L] Servei de Patologia, Hospital del Mar, Barcelona, Spain. [Vidal C] Institut Català d’Oncologia (ICO), Barcelona, Spain. [Saladié F] Cancer Epidemiology and Prevention Service, Hospital Universitari Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain. [Alcándara R] Servei de Diagnòstic per la Imatge, Hospital del Mar, Barcelona, Spain. [Sánchez M] Direction General of Public Health, Cantabria, Spain. [Quintana MJ] Department of Clinical Epidemiology and Public Health, University Hospital de La Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain. CIBER of Epidemiology and Public Health (CIBERESP), Spain. [Del Riego J] Women’s Imaging, Department of Radiology, UDIAT Centre Diagnòstic, Parc Taulí Hospital Universitari, Sabadell, Spain. [Ferrer J] Radiology Department, Hospital de Santa Caterina, Institut d’Assistència Sanitària (IAS), Salt, Spain
Institut d'Assistència Sanitària
2022-02-08T14:32:17Z
2022-02-08T14:32:17Z
2020-10-03
Neoplàsies de mama; Detecció precoç del càncer; Factors de risc
Neoplasias de mama; Detección precoz del cáncer; Factores de riesgo
Breast neoplasms; Early cancer detection; Risk factors
Introduction: We aimed to assess differences in breast cancer risk across benign breast disease diagnosed at prevalent or incident screens. Materials and methods: We conducted a retrospective cohort study with data from 629,087 women participating in a long-standing population-based breast cancer screening program in Spain. Each benign breast disease was classified as non-proliferative, proliferative without atypia, or roliferative with atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer. Results: Compared with women without benign breast disease, the risk of breast cancer was significantly higher (p-value ¼ 0.005) in women with benign breast disease diagnosed in an incident screen (aHR, 2.67; 95%CI: 2.24e3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR, 1.87; 95%CI: 1.57e2.24). The highest risk was found in women with a proliferative benign breast disease with atypia (aHR, 4.35; 95%CI: 2.09e9.08, and 3.35; 95%CI: 1.51e7.40 for those diagnosed at incident and prevalent screens, respectively), while the lowest was found in women with non-proliferative benign breast disease (aHR, 2.39; 95%CI: 1.95e2.93, and 1.63; 95%CI: 1.32e2.02 for those diagnosed at incident and prevalent screens, respectively). Conclusion: Our study showed that the risk of breast cancer conferred by a benign breast disease differed according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the impact of the screening type on benign breast disease prognosis
This study was supported by grants from Instituto de Salud Carlos III FEDER (grant numbers: PI15/00098 and PI17/00047), and by the Research Network on Health Services in Chronic Diseases (RD12/0001/0015)
Article
Published version
English
Mama - Càncer - Diagnòstic; Mama - Càncer - Factors de risc; Mama - Malalties - Imatgeria; DISEASES::Skin and Connective Tissue Diseases::Skin Diseases::Breast Diseases::Breast Neoplasms; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Radiography::Mammography; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors; ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::enfermedades de la mama::neoplasias de la mama; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::radiografía::mamografía; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo
Elsevier
Churchill Livingstone
The Breast;54
https://doi.org/10.1016/j.breast.2020.09.005
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
